Literature DB >> 22101245

Targeting and utilizing primary tumors as live vaccines: changing strategies.

Xuanming Yang1, Eric D Mortenson, Yang-Xin Fu.   

Abstract

Tumor metastases and relapse are the major causes of morbidity and mortality in cancer. Although surgery, chemotherapy and/or radiation therapy can typically control primary tumor growth, metastatic and relapsing tumors are often inaccessible or resistant to these treatments. An adaptive immune response can be generated during these conventional treatments of the primary tumor, and presumably both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system. Thus, when established, this response should be able to control metastatic growth and tumor relapse. This review summarizes the mechanisms by which antitumor immune responses are generated, and recent findings supporting the hypothesis that many therapies targeting primary tumors can generate antitumor adaptive immune responses to prevent metastases and tumor relapse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101245      PMCID: PMC4002936          DOI: 10.1038/cmi.2011.49

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  75 in total

1.  Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway.

Authors:  K Tamada; K Shimozaki; A I Chapoval; G Zhu; G Sica; D Flies; T Boone; H Hsu; Y X Fu; S Nagata; J Ni; L Chen
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

2.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

Review 3.  Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development.

Authors:  N H Ruddle
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 4.  How genetically engineered mouse tumor models provide insights into human cancers.

Authors:  Katerina Politi; William Pao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

5.  The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells.

Authors:  I A Rooney; K D Butrovich; A A Glass; S Borboroglu; C A Benedict; J C Whitbeck; G H Cohen; R J Eisenberg; C F Ware
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

6.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors:  Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

7.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 8.  Tolerance and ways to break it.

Authors:  G J Nossal
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

Review 9.  Lymphoid neogenesis in chronic inflammatory diseases.

Authors:  Francesca Aloisi; Ricardo Pujol-Borrell
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

10.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

View more
  3 in total

1.  Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.

Authors:  Dongjun Peng; Takashi Tanikawa; Wei Li; Lili Zhao; Linda Vatan; Wojciech Szeliga; Shanshan Wan; Shuang Wei; Yin Wang; Yan Liu; Elzbieta Staroslawska; Franciszek Szubstarski; Jacek Rolinski; Ewelina Grywalska; Andrzej Stanisławek; Wojciech Polkowski; Andrzej Kurylcio; Celina Kleer; Alfred E Chang; Max Wicha; Michael Sabel; Weiping Zou; Ilona Kryczek
Journal:  Cancer Res       Date:  2016-04-06       Impact factor: 12.701

2.  Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.

Authors:  Eric D Mortenson; SaeGwang Park; Zhujun Jiang; Shengdian Wang; Yang-Xin Fu
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

3.  Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation.

Authors:  Jun Zhu; Yan Zhang; Aili Zhang; Kun He; Ping Liu; Lisa X Xu
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.